Equity Overview
Price & Market Data
Price: $2.28
Daily Change: $0.00 / 0.00%
Daily Range: $1.96 - $2.29
Market Cap: $64,649,996
Daily Volume: 962,628
Performance Metrics
1 Week: 6.05%
1 Month: -15.56%
3 Months: -34.10%
6 Months: 7.04%
1 Year: 43.40%
YTD: -34.10%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.